Last Updated on October 13, 2021 by The Health Master
Molbio Diagnostics, the innovator of Truenat, a point of care Real-Time PCR platform, received Drug Controller General of India (DCGI) approval for its Truenat Scrub T test for Scrub Typhus, an infectious disease that can spread to humans through the bite of an infected chigger (larval mites).
Scrub Typhus affects approximately one million people in India every year. As per the PLOS report July 2021, the highest densities of cases were from Tamil Nadu (37.6% of cases), Himachal Pradesh (11%), Karnataka (8.8%), and Uttrakhand (8.5%).
Early detection is crucial for effective treatment and low mortality. Without appropriate treatment, the case fatality rate of scrub typhus can reach 30% or even higher.
Real-Time PCR is the most accurate and sensitive method of diagnosis of infection with Scrub Typhus. With Truenat testing at point of care, the disease can be detected at an early stage efficiently and can be controlled effectively.
Sriram Natarajan, founder-director and CEO of Molbio Diagnostics said, “We have addressed the critical need for reliable technologies that can enable early and accurate diagnosis by making molecular testing accessible & affordable.
We are very happy that our Truenat test for Scrub Typhus has now been approved by DCGI. This will help in fighting against the disease and prevent unnecessary morbidity and mortality.”
“Quality healthcare should be proactive and not reactive. Enabling point-of-care testing systems are a crucial part of this process. Truenat is a platform that has the approval to test 30+ diseases, the latest being Scrub Typhus.
This allows healthcare facilities the flexibility of ramping up testing for specific diseases when required without having to invest in new facilities and amenities. The single platform, Truenat, can test for all diseases with just a different chip. This is the perfect solution for quality healthcare.” Dr. Chandrasekhar Nair, director & CTO, Molbio Diagnostics added.
Truenat is globally recognized and endorsed as a true point-of-care molecular diagnostic platform that can test multiple diseases. This revolutionary technology is already helping in reducing the spread of various infectious diseases like C-19, tuberculosis, H1N1, dengue, hepatitis and more.